Christopher D. Lao

TL;DR: In this article , a subset of patients experienced paradoxical rapid cancer progression during immunotherapy, and it is poorly understood how tumors can accelerate their progression during ICB, while immune exclusion drives resistance to ICB and counterintuitively, patients with HPD and complete response following ICB manifest comparable levels of tumor-infiltrating CD8+ T cells and interferon γ (IFNγ) gene signature.

TL;DR: Over the next decade, the emergence of molecular and proteomic profiling tools have the potential of selecting adenomas that will progress to adenocarcinomas and will allow for investigation to be focused on individuals at increased risk.

TL;DR: In this paper , the safety and efficacy of NIVO ± IPI in pts with R/M Cx Ca in CheckMate 358 (NCT02488759) was reported.

TL;DR: Dramatic partial responses of 2 patients with melanoma brain metastases treated with the experimental radiosensitizer RRx-001 are reported, at the lowest dose of 5 mg/m, and whole brain radiotherapy (WBRT) in the context of a dose escalation phase I/II trial acronymed BRAINSTORM at the University of Michigan.

TL;DR: A case of a KIT double mutation in anorectal melanoma not previously described in melanoma, but with a response to imatinib mesylate that might have been expected given the knowledge from other cancers is reported.